DelveInsight Business Research LLP
(United States, Nevada, Las Vegas), DelveInsight’s “Antibody Drug Conjugate- Competitive landscape, 2023,” report provides comprehensive insights about 180+ companies and 300+ drugs in Antibody Drug Conjugate Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive ADC pipeline products in this space. pipeline products in this space.

Key Takeaways from the Antibody Drug Conjugate Competitive Landscape Report

  • Over 180+ companies and 300+ pipeline drugs in Antibody Drug Conjugate are in various stages of development, and their anticipated acceptance in the Antibody Drug Conjugate market would significantly increase market revenue. 

  • Leading Antibody Drug Conjugate companies developing novel drug candidates to improve the Antibody Drug Conjugate treatment landscape include NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc.

  • Promising Antibody Drug Conjugate pipeline therapies in various stages of development include Bardoxolone and others.

Antibody Drug Conjugate Overview

Antibody–drug conjugates (ADC) are one of the fastest-growing anticancer drugs. This approach comprises a mAb conjugated to the cytotoxic payload via a chemical linker that is directed toward a target antigen expressed on the cancer cell surface, reducing systemic exposure and therefore toxicity. ADCs are complex molecules that require careful attention to various components. The selection of an appropriate target, a mAb, cytotoxic payload, and the manner in which the antibody is linked to the payload are key determinants of the safety and efficacy of ADCs. Antibody–drug conjugate (ADC) is a new emerging class of highly potent pharmaceutical drugs, which is a great combination of chemotherapy and immunotherapy. 

The concept of ADC was first presented by German physician and scientist Paul Ehrlich almost 100 years before. One of the most important aspects of ADC development for cancer is the identification of the unique antigenic target of the mAb component. There are 328 unique antigens used in antibody-based therapy as a target. The selected antigen needs to fulfill several requirements. First, the target antigen needs to have high expression in the tumor and no or low expression in the healthy cell. 

Second, the target antigen should be displayed on the surface of the tumor cell to be available to the circulated mAb. Third, the target antigen should possess internalization properties as it will facilitate the ADC to transport into the cell, which will in turn enhance the efficacy of the cytotoxic agent. In ADCs, the most targeted antigens are ERBB2, CD19, CD33, CD22, and MSLN (mesothelin).

Discover more about the emerging Antibody Drug Conjugate drugs @ Antibody Drug Conjugate Treatment Drugs

Antibody Drug Conjugate Pipeline Therapies and Key Companies

  • Pfizer: MYLOTARG

  • AstraZeneca:  Enhertu

  • ADC Therapeutics: Ladiratuzumab Vedotin

  • ImmunoGen:  IMGN151

And many others 

Antibody Drug Conjugate Pipeline Therapeutics Assessment

Scope of the Antibody Drug Conjugate Pipeline Report 

  • Coverage: Global 

  • Key Antibody Drug Conjugate Companies: NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Merck KGaA, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Sanofi, Navrogen, Inc., and others.

  • Key Antibody Drug Conjugate  Pipeline Therapies: MYLOTARG, Enhertu,  Zynlonta, Ladiratuzumab Vedotin, IMGN151, NBE-002, and many others.

Find out more about the Antibody Drug Conjugate treatment options in development @ Antibody Drug Conjugate Clinical Trials

Table of Contents

1 Introduction

2 Executive Summary

3 CAR T – Cell Therapy: Overview

 3.1 Introduction

           3.2 Mechanism of Action

           3.3 Application

           3.4 Limitation

 3.5 Approved Therapies

4 Antibody Drug Conjugate -Analytical Perspective: In-depth Commercial Assessment

4.1 Antibody Drug Conjugate Collaboration Analysis by Companies

Competitive Landscape

4.2 Comparative Assessment of Companies (by therapy, development stage, and technology)

5 Therapeutic Assessment

   5.1 Assessment by Product Type

   5.2 Assessment by Stage and Product Type

   5.3Assessment by Route of Administration

   5.4 Assessment by Stage and Route of Administration

   5.5Assessment by Molecule Type

   5.6Assessment by Stage and Molecule Type

 

6 Antibody Drug Conjugate: Company and Product Profiles (Marketed Therapies)

      JW Therapeutics

6.1 Company Overview

Relmacabtagene Autoleucel

6.2 Product Description

6.3 Research and Development Activities

          6.4Product Developmental Activities

7 Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)

7.1 Late-Stage Products (Registered)

           Comparative Analysis

7.2 CARsgen

Company Overview

Zevorcabtagene autoleucel

Product Description

Research and Development Activities

Product Developmental Activities

Drug profiles in the detailed report…..

7.3 Mid-Stage Products (Phase II)

Comparative Analysis

Cartesian Therapeutics

Company Overview

Descartes 011

Product Description

Research and Development Activities

Product Developmental Activities

Drug profiles in the detailed report…..

7.4 Early Stage Products (Phase I)

Comparative Analysis

Autolus Therapeutics

Company Overview

AUTO-8

Product Description

Research and Development Activities

Product Developmental Activities

Drug profiles in the detailed report…..

7.5 Preclinical and Discovery Stage Products

Comparative Analysis

Sana Biotechnology

Company Overview

SG299

Product Description

Research and Development Activities

Product Developmental Activities

Drug profiles in the detailed report…..

7.6 Inactive Products

Comparative Analysis

7.7 CAR T – Cell Therapy – Unmet needs

7.8 CAR T – Cell Therapy– Market drivers and barriers

Appendix

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Leave a Reply

Your email address will not be published. Required fields are marked *